Study wrapper · #1178
Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.
Editor's note
This Polish EHR study tracks what happens to background diabetes medications after patients start semaglutide, tirzepatide, or older GLP-1 agents. Additional glucose-lowering substances were recorded more often than they were removed, with tirzepatide starters showing the lowest rate of added therapy at 20.4 percent versus 52.9 percent for dulaglutide. The authors are appropriately careful: these are prescription-record patterns, not proof of actual exposure or a causal difference between agents.
Plain-language abstract
Polish health records from 3,660 adults with type 2 diabetes show that after starting a GLP-1 drug, most patients kept or added other glucose-lowering medications rather than dropping them. Patients starting tirzepatide were the least likely to have additional drugs recorded afterward.